---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-25-000067"
form_type: "8-K"
ticker: "LNAI"
cik: "0001527728"
company_name: "Lunai Bioworks Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:11:21.239716+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Renovaro appoints Nathen Fuentes as CFO; removes interim CFO Simon Tarsh

## Summary
- Nathen Fuentes, age 42, appointed CFO effective January 6, 2025; previously CFO at Telomir Pharmaceuticals (Sep 2023 – Jun 2024).
- Base salary of $280,000 per year; performance bonus up to $40,000 annually, pro-rated for 2025.
- Equity incentive grant of 250,000 stock options vesting quarterly over eight quarters; discretionary equity grant on first anniversary.
- If terminated without cause or for good reason: six months base salary, COBRA reimbursement for 6 months, accelerated vesting of time-based awards.
- Simon Tarsh removed as Interim CFO in connection with Fuentes' appointment.

## SEC filing metadata
- accession: 0001731122-25-000067
- form_type: 8-K
- ticker: LNAI
- cik: 0001527728
- company_name: Lunai Bioworks Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/0001731122-25-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/e6282_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-25-000067
- JSON: https://secwatch.observer/filing/0001731122-25-000067.json
- Plain text: https://secwatch.observer/filing/0001731122-25-000067.txt

## Key facts
- Executive change
  Simon Tarsh was removed as Interim Chief Financial Officer at Lunai Bioworks Inc..
  - Action: removed
  - Role: Interim Chief Financial Officer
  source text: In connection with Mr. Fuentes’ appointment as Chief Financial Officer, Simon Tarsh was removed as Interim Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/0001731122-25-000067-index.htm
- Executive change
  Nathen Fuentes was appointed as Chief Financial Officer at Lunai Bioworks Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective January 6, 2025, the board of directors (the “ Board ”) of Renovaro Inc. (the “ Company ” or “ Renovaro ”) appointed Nathen Fuentes, age 42, as Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/0001731122-25-000067-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.